- Home
- ONCO vs SPRB Comparison
ONCO vs SPRB Comparison
Compare ONCO & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- SPRB
- Stock Information
- Founded
- ONCO 2018
- SPRB 2014
- Country
- ONCO United States
- SPRB United States
- Employees
- ONCO N/A
- SPRB N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- ONCO Health Care
- SPRB Health Care
- Exchange
- ONCO Nasdaq
- SPRB Nasdaq
- Market Cap
- ONCO 24.1M
- SPRB 22.8M
- IPO Year
- ONCO 2022
- SPRB 2020
- Fundamental
- Price
- ONCO $1.27
- SPRB $0.49
- Analyst Decision
- ONCO
- SPRB Hold
- Analyst Count
- ONCO 0
- SPRB 7
- Target Price
- ONCO N/A
- SPRB $2.50
- AVG Volume (30 Days)
- ONCO 71.6K
- SPRB 399.6K
- Earning Date
- ONCO 11-26-2024
- SPRB 11-11-2024
- Dividend Yield
- ONCO N/A
- SPRB N/A
- EPS Growth
- ONCO N/A
- SPRB N/A
- EPS
- ONCO N/A
- SPRB N/A
- Revenue
- ONCO $1,463,746.00
- SPRB $7,101,000.00
- Revenue This Year
- ONCO N/A
- SPRB N/A
- Revenue Next Year
- ONCO N/A
- SPRB N/A
- P/E Ratio
- ONCO N/A
- SPRB N/A
- Revenue Growth
- ONCO N/A
- SPRB N/A
- 52 Week Low
- ONCO $1.27
- SPRB $0.41
- 52 Week High
- ONCO $21.40
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- ONCO 20.68
- SPRB 41.68
- Support Level
- ONCO $1.70
- SPRB $0.50
- Resistance Level
- ONCO $2.53
- SPRB $0.54
- Average True Range (ATR)
- ONCO 0.28
- SPRB 0.03
- MACD
- ONCO -0.14
- SPRB -0.01
- Stochastic Oscillator
- ONCO 0.00
- SPRB 2.15
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).